{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T13:43:08Z","timestamp":1777038188929,"version":"3.51.4"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA048026"],"award-info":[{"award-number":["R01DA048026"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.cct.2021.106603","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T08:09:42Z","timestamp":1634890182000},"page":"106603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeting white matter neuroprotection as a relapse prevention strategy for treatment of cocaine use disorder: Design of a mechanism-focused randomized clinical trial"],"prefix":"10.1016","volume":"111","author":[{"given":"Joy M.","family":"Schmitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott D.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael F.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ponnada A.","family":"Narayana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khader M.","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DeLisa D.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Suchting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles E.","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cct.2021.106603_bb0005","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/10826084.2019.1664592","article-title":"Is cocaine coming back? A Commentary","volume":"55","author":"Maxwell","year":"2020","journal-title":"Subst. Use Misuse"},{"issue":"1","key":"10.1016\/j.cct.2021.106603_bb0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13011-021-00350-5","article-title":"\u2018Resurgent\u2019, \u2018twin\u2019 or \u2018silent\u2019 epidemic? A select data overview and observations on increasing psycho-stimulant use and harms in North America","volume":"16","author":"Fischer","year":"2021","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"3","key":"10.1016\/j.cct.2021.106603_bb0015","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.psc.2010.04.012","article-title":"Cognitive behavioral therapy for substance use disorders","volume":"33","author":"McHugh","year":"2010","journal-title":"Psychiatr Clin North Am."},{"issue":"7","key":"10.1016\/j.cct.2021.106603_bb0020","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11920-016-0703-4","article-title":"New directions in medication-facilitated behavioral treatment for substance use disorders","volume":"18","author":"Dakwar","year":"2016","journal-title":"Curr Psychiatry Rep."},{"key":"10.1016\/j.cct.2021.106603_bb0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.drugalcdep.2019.03.023","article-title":"Regional differences in white matter integrity in stimulant use disorders: a meta-analysis of diffusion tensor imaging studies","volume":"201","author":"Beard","year":"2019","journal-title":"Drug Alcohol Depend."},{"issue":"2","key":"10.1016\/j.cct.2021.106603_bb0030","doi-asserted-by":"crossref","first-page":"e12902","DOI":"10.1111\/adb.12902","article-title":"A meta-analysis of tract-based spatial statistics studies examining white matter integrity in cocaine use disorder","volume":"26","author":"Suchting","year":"2021","journal-title":"Addict. Biol."},{"issue":"7","key":"10.1016\/j.cct.2021.106603_bb0035","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1038\/npp.2010.25","article-title":"White matter integrity is associated with treatment outcome measures in cocaine dependence","volume":"35","author":"Xu","year":"2010","journal-title":"Neuropsychopharmacol."},{"issue":"7","key":"10.1016\/j.cct.2021.106603_bb0040","doi-asserted-by":"crossref","first-page":"768","DOI":"10.2174\/1389450111314070006","article-title":"Peroxisome proliferator-activated receptor (PPAR) agonists as promising new medications for drug addiction: preclinical evidence","volume":"14","author":"Le Foll","year":"2013","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.cct.2021.106603_bb0045","doi-asserted-by":"crossref","first-page":"728461","DOI":"10.1155\/2012\/728461","article-title":"New insights into the role of peroxisome proliferator-activated receptors in regulating the inflammatory response after tissue injury","volume":"2012","author":"Neher","year":"2012","journal-title":"PPAR Res."},{"issue":"2","key":"10.1016\/j.cct.2021.106603_bb0050","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.expneurol.2011.02.002","article-title":"Broad-spectrum neuroprotection against traumatic brain injury by agonism of peroxisome proliferator-activated receptors","volume":"229","author":"Semple","year":"2011","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.cct.2021.106603_bb0055","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/adb.12471","article-title":"PPARgamma agonism attenuates cocaine cue reactivity","volume":"23","author":"Miller","year":"2018","journal-title":"Addict. Biol."},{"issue":"10","key":"10.1016\/j.cct.2021.106603_bb0060","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/add.13868","article-title":"PPAR-gamma agonist pioglitazone modifies craving intensity and brain white matter integrity in patients with primary cocaine use disorder: a double-blind randomized controlled pilot trial","volume":"112","author":"Schmitz","year":"2017","journal-title":"Addiction."},{"key":"10.1016\/j.cct.2021.106603_bb0065","series-title":"Relapse prevention for addictive behaviors. Substance abuse treatment, prevention, and policy","first-page":"17","volume":"6","author":"Hendershot","year":"2011"},{"issue":"1","key":"10.1016\/j.cct.2021.106603_bb0070","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1037\/1064-1297.4.1.46","article-title":"Relapse prevention as a psychosocial treatment: a review of controlled clinical trials","volume":"4","author":"Carroll","year":"1996","journal-title":"Experimental and Clinical Psychopharacology."},{"issue":"4","key":"10.1016\/j.cct.2021.106603_bb0075","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1037\/0022-006X.67.4.563","article-title":"Efficacy of relapse prevention: a meta-analytic review","volume":"67","author":"Irvin","year":"1999","journal-title":"J. Consult. Clin. Psychol."},{"issue":"4","key":"10.1016\/j.cct.2021.106603_bb0080","doi-asserted-by":"crossref","first-page":"516","DOI":"10.15288\/jsad.2009.70.516","article-title":"Cognitive-behavioral treatment with adult alcohol and illicit drug users: a meta-analysis of randomized controlled trials","volume":"70","author":"Magill","year":"2009","journal-title":"J Stud Alcohol Drugs."},{"issue":"2","key":"10.1016\/j.cct.2021.106603_bb0085","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00213-011-2485-z","article-title":"Neuropsychological profiling of impulsivity and compulsivity in cocaine dependent individuals","volume":"219","author":"Fernandez-Serrano","year":"2012","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.cct.2021.106603_bb0090","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/13803390490515694","article-title":"Neurocognitive deficits in cocaine users: a quantitative review of the evidence","volume":"27","author":"Jovanovski","year":"2005","journal-title":"J. Clin. Exp. Neuropsychol."},{"issue":"5","key":"10.1016\/j.cct.2021.106603_bb0095","first-page":"447","article-title":"The impact of clinical and demographic variables on cognitive performance in methamphetamine-dependent individuals in rural South Carolina","volume":"20","author":"Price","year":"2011","journal-title":"The American journal on addictions \/ American Academy of Psychiatrists in Alcoholism and Addictions."},{"issue":"2","key":"10.1016\/j.cct.2021.106603_bb0100","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1369-1600.2011.00418.x","article-title":"Widespread and sustained cognitive deficits in alcoholism: a meta-analysis","volume":"18","author":"Stavro","year":"2013","journal-title":"Addict. Biol."},{"issue":"3","key":"10.1016\/j.cct.2021.106603_bb0105","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.pscychresns.2009.11.003","article-title":"Working memory fMRI activation in cocaine-dependent subjects: association with treatment response","volume":"181","author":"Moeller","year":"2010","journal-title":"Psychiatry Res."},{"issue":"7","key":"10.1016\/j.cct.2021.106603_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011591","article-title":"Diffusion tensor imaging and decision making in cocaine dependence","volume":"5","author":"Lane","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.cct.2021.106603_bb0115","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.nicl.2015.03.015","article-title":"Inhibitory behavioral control: a stochastic dynamic causal modeling study comparing cocaine dependent subjects and controls","volume":"7","author":"Ma","year":"2015","journal-title":"Neuroimage Clin."},{"issue":"3","key":"10.1016\/j.cct.2021.106603_bb0120","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.drugalcdep.2005.08.003","article-title":"Cognitive deficits predict low treatment retention in cocaine dependent patients","volume":"81","author":"Aharonovich","year":"2006","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.cct.2021.106603_bb0125","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0740-5472(01)00202-1","article-title":"The impact of impulsivity on cocaine use and retention in treatment","volume":"21","author":"Moeller","year":"2001","journal-title":"J. Subst. Abus. Treat."},{"issue":"3","key":"10.1016\/j.cct.2021.106603_bb0130","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/10550880903028502","article-title":"Baseline neurocognitive profiles differentiate abstainers and non-abstainers in a cocaine clinical trial","volume":"28","author":"Schmitz","year":"2009","journal-title":"J. Addict. Dis."},{"issue":"2","key":"10.1016\/j.cct.2021.106603_bb0135","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0376-8716(03)00092-9","article-title":"Cognitive impairment, retention and abstinence among cocaine abusers in cognitive-behavioral treatment","volume":"71","author":"Aharonovich","year":"2003","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"10.1016\/j.cct.2021.106603_bb0140","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1037\/0893-164X.20.3.241","article-title":"Cognitive impairment influences drinking outcome by altering therapeutic mechanisms of change","volume":"20","author":"Bates","year":"2006","journal-title":"Psychol. Addict. Behav."},{"issue":"1","key":"10.1016\/j.cct.2021.106603_bb0145","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/10826084.2011.521069","article-title":"Cognitive function and treatment response in a randomized clinical trial of computer-based training in cognitive-behavioral therapy","volume":"46","author":"Carroll","year":"2011","journal-title":"Subst. Use Misuse"},{"issue":"9","key":"10.1016\/j.cct.2021.106603_bb0150","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1038\/npp.2014.71","article-title":"Cognitive impairment in cocaine users is drug-induced but partially reversible: evidence from a longitudinal study","volume":"39","author":"Vonmoos","year":"2014","journal-title":"Neuropsychopharmacology."},{"issue":"2","key":"10.1016\/j.cct.2021.106603_bb0155","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/wps.20227","article-title":"The NIMH experimental medicine initiative","volume":"14","author":"Insel","year":"2015","journal-title":"World Psychiatry"},{"issue":"5","key":"10.1016\/j.cct.2021.106603_bb0160","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1152\/jn.00221.2016","article-title":"White matter and cognition: making the connection","volume":"116","author":"Filley","year":"2016","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.cct.2021.106603_bb0165","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.pneurobio.2017.10.002","article-title":"Peroxisome proliferator-activated receptor gamma (PPARgamma): A master gatekeeper in CNS injury and repair","volume":"163-164","author":"Cai","year":"2018","journal-title":"Prog. Neurobiol."},{"issue":"6","key":"10.1016\/j.cct.2021.106603_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19061639","article-title":"Metabolic dysfunction and Peroxisome Proliferator-Activated Receptors (PPAR) in multiple sclerosis","volume":"19","author":"Ferret-Sena","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.cct.2021.106603_bb0175","doi-asserted-by":"crossref","DOI":"10.1042\/AN20130030","article-title":"PPAR agonists as therapeutics for CNS trauma and neurological diseases","volume":"5","author":"Mandrekar-Colucci","year":"2013","journal-title":"ASN Neuro."},{"issue":"4","key":"10.1016\/j.cct.2021.106603_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041212","article-title":"Demyelination in Multiple Sclerosis: Reprogramming Energy Metabolism and Potential PPARgamma Agonist Treatment Approaches","volume":"19","author":"Vallee","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.cct.2021.106603_bb0185","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/mds.26312","article-title":"Gray and white matter imaging: a biomarker for cognitive impairment in early Parkinson\u2019s disease?","volume":"31","author":"Duncan","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.cct.2021.106603_bb0190","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.msard.2019.02.021","article-title":"Cognitive speed and white matter integrity in secondary progressive multiple sclerosis","volume":"30","author":"Manca","year":"2019","journal-title":"Mult Scler Relat Disord."},{"issue":"11","key":"10.1016\/j.cct.2021.106603_bb0195","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1177\/1352458515622694","article-title":"White matter tract abnormalities are associated with cognitive dysfunction in secondary progressive multiple sclerosis","volume":"22","author":"Meijer","year":"2016","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.cct.2021.106603_bb0200","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/1097-4679(197110)27:4<455::AID-JCLP2270270412>3.0.CO;2-R","article-title":"Relapse rates in addiction programs","volume":"27","author":"Hunt","year":"1971","journal-title":"J. Clin. Psychol."},{"issue":"1","key":"10.1016\/j.cct.2021.106603_bb0205","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jsat.2008.04.001","article-title":"A quantitative review of the ubiquitous relapse curve","volume":"36","author":"Kirshenbaum","year":"2009","journal-title":"J. Subst. Abus. Treat."},{"issue":"2","key":"10.1016\/j.cct.2021.106603_bb0210","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.drugalcdep.2004.02.007","article-title":"Choosing a behavioral therapy platform for pharmacotherapy of substance users","volume":"75","author":"Carroll","year":"2004","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"10.1016\/j.cct.2021.106603_bb0215","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1001\/archpsyc.61.3.264","article-title":"Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial","volume":"61","author":"Carroll","year":"2004","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.cct.2021.106603_bb0220","first-page":"19","article-title":"Integrating psychotherapy and pharmacotherapy for cocaine dependence: results from a randomized clinical trial","volume":"150","author":"Carroll","year":"1995","journal-title":"NIDA Res. Monogr."},{"issue":"2","key":"10.1016\/j.cct.2021.106603_bb0225","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0306-4603(00)00098-8","article-title":"Naltrexone and relapse prevention treatment for cocaine-dependent patients","volume":"26","author":"Schmitz","year":"2001","journal-title":"Addict. Behav."},{"issue":"1\u20133","key":"10.1016\/j.cct.2021.106603_bb0230","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.drugalcdep.2007.11.004","article-title":"Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform","volume":"94","author":"Schmitz","year":"2008","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"10.1016\/j.cct.2021.106603_bb0235","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0376-8716(99)00049-6","article-title":"A general system for evaluating therapist adherence and competence in psychotherapy research in the addictions","volume":"57","author":"Carroll","year":"2000","journal-title":"Drug Alcohol Depend."},{"issue":"10","key":"10.1016\/j.cct.2021.106603_bb0240","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1017\/S1461145710000970","article-title":"Is there a role for the nuclear receptor PPARgamma in neuropsychiatric diseases?","volume":"13","author":"Garcia-Bueno","year":"2010","journal-title":"The international journal of neuropsychopharmacology \/ official scientific journal of the Collegium Internationale Neuropsychopharmacologicum."},{"issue":"2","key":"10.1016\/j.cct.2021.106603_bb0245","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.expneurol.2011.09.001","article-title":"Ketogenic diet-induced peroxisome proliferator-activated receptor-gamma activation decreases neuroinflammation in the mouse hippocampus after kainic acid-induced seizures","volume":"232","author":"Jeong","year":"2011","journal-title":"Exp. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.cct.2021.106603_bb0250","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jneuroim.2009.04.011","article-title":"A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis","volume":"211","author":"Kaiser","year":"2009","journal-title":"J. Neuroimmunol."},{"issue":"11","key":"10.1016\/j.cct.2021.106603_bb0255","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1345\/aph.1Q238","article-title":"Rosiglitazone and pioglitazone for the treatment of Alzheimer\u2019s disease","volume":"45","author":"Miller","year":"2011","journal-title":"Ann. Pharmacother."},{"issue":"4","key":"10.1016\/j.cct.2021.106603_bb0260","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.addbeh.2004.02.010","article-title":"The blind spot in the nicotine replacement therapy literature: assessment of the double-blind in clinical trials","volume":"29","author":"Mooney","year":"2004","journal-title":"Addict. Behav."},{"key":"10.1016\/j.cct.2021.106603_bb0265","series-title":"Structured Clinical Interview for DSM-5-Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV)","author":"First","year":"2015"},{"issue":"3","key":"10.1016\/j.cct.2021.106603_bb0270","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0740-5472(92)90062-S","article-title":"The fifth edition of the addiction severity index","volume":"9","author":"McLellan","year":"1992","journal-title":"J. Subst. Abus. Treat."},{"issue":"2","key":"10.1016\/j.cct.2021.106603_bb0275","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0376-8716(02)00308-3","article-title":"The Kreek-McHugh-Schluger-Kellogg scale: a new, rapid method for quantifying substance abuse and its possible applications","volume":"69","author":"Kellogg","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.cct.2021.106603_bb0280","series-title":"Alcohol Timeline Followback Users\u2019 Manual","author":"Sobbell","year":"1995"},{"issue":"8","key":"10.1016\/j.cct.2021.106603_bb0285","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.mri.2007.02.011","article-title":"A framework for quality control and parameter optimization in diffusion tensor imaging: theoretical analysis and validation","volume":"25","author":"Hasan","year":"2007","journal-title":"Magn. Reson. Imaging"},{"issue":"12","key":"10.1016\/j.cct.2021.106603_bb0290","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.compbiomed.2010.10.008","article-title":"A review of diffusion tensor magnetic resonance imaging computational methods and software tools","volume":"41","author":"Hasan","year":"2011","journal-title":"Comput. Biol. Med."},{"issue":"5","key":"10.1016\/j.cct.2021.106603_bb0295","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1089\/neu.2013.3085","article-title":"Serial atlas-based diffusion tensor imaging study of uncomplicated mild traumatic brain injury in adults","volume":"31","author":"Hasan","year":"2014","journal-title":"J. Neurotrauma"},{"issue":"11 Suppl 3","key":"10.1016\/j.cct.2021.106603_bb0300","first-page":"S54","article-title":"Cognition assessment using the NIH toolbox","volume":"80","author":"Weintraub","year":"2013","journal-title":"Neurology."},{"issue":"4","key":"10.1016\/j.cct.2021.106603_bb0305","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/mono.12038","article-title":"VIII. NIH toolbox cognition battery (CB): composite scores of crystallized, fluid, and overall cognition","volume":"78","author":"Akshoomoff","year":"2013","journal-title":"Monogr. Soc. Res. Child Dev."},{"issue":"2","key":"10.1016\/j.cct.2021.106603_bb0310","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.molmed.2017.12.007","article-title":"Addiction biomarkers: dimensional approaches to understanding addiction","volume":"24","author":"Kwako","year":"2018","journal-title":"Trends Mol. Med."},{"issue":"3","key":"10.1016\/j.cct.2021.106603_bb0315","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.biopsych.2015.10.024","article-title":"Addictions Neuroclinical assessment: a neuroscience-based framework for addictive disorders","volume":"80","author":"Kwako","year":"2016","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.cct.2021.106603_bb0320","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1300\/J069v20n03_07","article-title":"The measurement of craving","volume":"20","author":"Mezinskis","year":"2001","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.cct.2021.106603_bb0325","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.drugalcdep.2014.01.012","article-title":"Toward empirical identification of a clinically meaningful indicator of treatment outcome: features of candidate indicators and evaluation of sensitivity to treatment effects and relationship to one year follow up cocaine use outcomes","volume":"137","author":"Carroll","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.cct.2021.106603_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.11.004","article-title":"Measures of outcome for stimulant trials: ACTTION recommendations and research agenda","volume":"158","author":"Kiluk","year":"2016","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.cct.2021.106603_bb0335","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1037\/a0036245","article-title":"What happens in treatment doesn\u2019t stay in treatment: cocaine abstinence during treatment is associated with fewer problems at follow-up","volume":"82","author":"Kiluk","year":"2014","journal-title":"J. Consult. Clin. Psychol."},{"issue":"2","key":"10.1016\/j.cct.2021.106603_bb0340","doi-asserted-by":"crossref","DOI":"10.4172\/2329-6488.1000108","article-title":"Measuring Outcome in the Treatment of Cocaine Dependence","volume":"1","author":"Crits-Christoph","year":"2013","journal-title":"Journal of alcoholism and drug dependence"},{"issue":"1","key":"10.1016\/j.cct.2021.106603_bb0345","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1360-0443.2011.03552.x","article-title":"Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms","volume":"107","author":"Oliveto","year":"2012","journal-title":"Addiction."},{"issue":"5 Suppl 1","key":"10.1016\/j.cct.2021.106603_bb0350","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.mlr.0000258615.42478.55","article-title":"The patient-reported outcomes measurement information system (PROMIS): progress of an NIH roadmap cooperative group during its first two years","volume":"45","author":"Cella","year":"2007","journal-title":"Med. Care"},{"issue":"7","key":"10.1016\/j.cct.2021.106603_bb0355","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s11136-009-9496-9","article-title":"Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items","volume":"18","author":"Hays","year":"2009","journal-title":"Qual. Life Res."},{"issue":"8","key":"10.1016\/j.cct.2021.106603_bb0360","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1111\/j.1530-0277.1996.tb01142.x","article-title":"Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer","volume":"20","author":"Del Boca","year":"1996","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.cct.2021.106603_bb0365","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.drugalcdep.2016.02.045","article-title":"Feasibility and success of cell-phone assisted remote observation of medication adherence (CAROMA) in clinical trials","volume":"163","author":"DeWorsop","year":"2016","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.cct.2021.106603_bb0370","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.drugalcdep.2003.11.007","article-title":"A replicable model for achieving over 90% follow-up rates in longitudinal studies of substance abusers","volume":"74","author":"Scott","year":"2004","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.cct.2021.106603_bb0375","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.cct.2011.03.010","article-title":"A comparison of two worlds: how does Bayes hold up to the status quo for the analysis of clinical trials?","volume":"32","author":"Pressman","year":"2011","journal-title":"Contemp Clin Trials."},{"issue":"1","key":"10.1016\/j.cct.2021.106603_bb0380","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jclinepi.2008.07.006","article-title":"Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials","volume":"62","author":"Wijeysundera","year":"2009","journal-title":"J. Clin. Epidemiol."},{"issue":"1","key":"10.1016\/j.cct.2021.106603_bb0385","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/add.13053","article-title":"Using Bayesian analysis for hypothesis testing in addiction science","volume":"111","author":"West","year":"2016","journal-title":"Addiction."},{"issue":"4","key":"10.1016\/j.cct.2021.106603_bb0390","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1191\/1740774505cn098oa","article-title":"Introduction to Bayesian methods I: measuring the strength of evidence","volume":"2","author":"Goodman","year":"2005","journal-title":"Clin Trials"},{"issue":"7020","key":"10.1016\/j.cct.2021.106603_bb0395","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1136\/bmj.311.7020.1621","article-title":"Clinical trials and rare diseases: a way out of a conundrum","volume":"311","author":"Lilford","year":"1995","journal-title":"Bmj."},{"issue":"4","key":"10.1016\/j.cct.2021.106603_bb0400","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/bimj.200510237","article-title":"FDA\u2019s critical path initiative: a perspective on contributions of biostatistics","volume":"48","author":"O\u2019Neill","year":"2006","journal-title":"Biom. J."},{"key":"10.1016\/j.cct.2021.106603_bb0405","series-title":"The Theory of Probability","author":"Jeffreys","year":"1961"},{"key":"10.1016\/j.cct.2021.106603_bb0410","series-title":"Bayesian Cognitive Modeling: A Practical Course","author":"Lee","year":"2014"},{"key":"10.1016\/j.cct.2021.106603_bb0415","unstructured":"Intrinsic reward sensitivity and smoking cessation with varenicline or patch NRT. [Internet]. NCT02162849."},{"key":"10.1016\/j.cct.2021.106603_bb0420","unstructured":"Varenicline and combined NRT for initial smoking cessation and rescue treatment in smokers [Internet]. NCT02271919."},{"key":"10.1016\/j.cct.2021.106603_bb0425","unstructured":"Ketamine for treatment resistant late-life depression [Internet]. NCT02556606."},{"key":"10.1016\/j.cct.2021.106603_bb0430","unstructured":"Low reward sensitivity and behavioral activation therapy for smoking cessation [Internet]. NCT02697227."},{"key":"10.1016\/j.cct.2021.106603_bb0435","unstructured":"Clinical trial of citalopram in cocaine dependence [Internet]. NCT01535573."},{"issue":"9209","key":"10.1016\/j.cct.2021.106603_bb0440","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/S0140-6736(00)02039-0","article-title":"Subgroup analysis and other (mis)uses of baseline data in clinical trials","volume":"355","author":"Assmann","year":"2000","journal-title":"Lancet."},{"issue":"19","key":"10.1016\/j.cct.2021.106603_bb0445","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1002\/sim.1296","article-title":"Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems","volume":"21","author":"Pocock","year":"2002","journal-title":"Stat. Med."},{"issue":"1","key":"10.1016\/j.cct.2021.106603_bb0450","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrd1927","article-title":"Bayesian clinical trials","volume":"5","author":"Berry","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cct.2021.106603_bb0455","series-title":"Bayesian data analysis, third edition","author":"Gelman","year":"2013"},{"key":"10.1016\/j.cct.2021.106603_bb0460","series-title":"Bayesian Approaches to Clinical Trials and Health-Care Evaluations","author":"Spiegelhalter","year":"2004"},{"issue":"22","key":"10.1016\/j.cct.2021.106603_bb0465","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/jnci\/88.22.1645","article-title":"Assessing whether to perform a confirmatory randomized clinical trial","volume":"88","author":"Parmar","year":"1996","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.cct.2021.106603_bb0470","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1214\/17-EJS1337SI","article-title":"Sparsity information and regularization in the horseshoe and other shrinkage priors","volume":"11","author":"Piironen","year":"2017","journal-title":"Electronic Journal of Statistics."},{"issue":"4","key":"10.1016\/j.cct.2021.106603_bb0475","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/pst.232","article-title":"Sample size and the probability of a successful trial","volume":"5","author":"Chuang-Stein","year":"2006","journal-title":"Pharm. Stat."},{"key":"10.1016\/j.cct.2021.106603_bb0480","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/pst.175","article-title":"Assurance in clinical trial design","volume":"4","author":"O\u2019Hagan","year":"2005","journal-title":"Pharm. Stat."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714421003396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714421003396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:54:22Z","timestamp":1761555262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714421003396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":96,"alternative-id":["S1551714421003396"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2021.106603","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting white matter neuroprotection as a relapse prevention strategy for treatment of cocaine use disorder: Design of a mechanism-focused randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2021.106603","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106603"}}